Autocrine secretion of osteopontin results in degradation of IκB in Bcr-Abl-expressing cells

British Journal of Haematology

Volumn 128, Issue 5, 2005, Pages 711-721

  Vejda, Susanne ^a,b   Piwocka, Katarzyna ^a   McKenna, Sharon L ^b   Cotter, Thomas G ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Bcr Abl; CML; Integrin signalling; Osteopontin; Tumour progression

Indexed keywords

BCR ABL PROTEIN; I KAPPA B; ISOPROTEIN; OSTEOPONTIN; RECEPTOR;

ADVANCED CANCER; ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; BONE MARROW; CELL DIFFERENTIATION; CELL INFILTRATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DNA MICROARRAY; EXPERIMENTAL MODEL; GENE EXPRESSION REGULATION; LEUKEMIA; LEUKEMIA CELL; MOLECULAR WEIGHT; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; DISEASE PROGRESSION; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; I-KAPPA B PROTEINS; LEUKEMIA, MYELOID, CHRONIC; MICE; OSTEOPONTIN; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 14844283122     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05355.x     Document Type: Article

References (52)

1. Amarante-Mendes, G.P., McGahon, A.J., Nishioka, W.K., Afar, D.E., Witte, O.N. & Green, D.R. (1998) Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene, 16, 1383-1390.
2. Arsura, M., Mercurio, F., Oliver, A.L., Thorgeirsson, S.S. & Sonenshein, G.E. (2000) Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Molecular and Cellular Biology, 20, 5381-5391.
3. Behrend, E.I., Craig, A.M., Wilson, S.M., Denhardt, D.T. & Chambers, A.F. (1994) Reduced malignancy of ras-transformed N1H 3T3 cells expressing antisense osteopontin RNA. Cancer Research, 54, 832-837.
4. Cao, Z., Tanaka, M., Regnier, C., Rothe, M., Yamit-hezi, A., Woronicz, J.D., Fuentes, M.E., Durnin, M.H., Dalrymple, S.A. & Goeddel, D.V. (1999) NF-kappa B activation by tumor necrosis factor and interleukin-1. Cold Spring Harbor Symposia on Quantitative Biology, 64, 473-483.
5. Chan, J.Y. & Watt, S.M. (2001) Adhesion receptors on haematopoietic progenitor cells. British Journal of Haematology, 112, 541-557.
6. Chang, P.L., Yang, W.C. & Prince, C.W. (1995) Effects of okadaic acid on calcitriol- and phorbol ester-induced expression and phosphorylation of osteopontin in mouse JB6 epidermal cells. Annals of the New York Academy of Sciences, 760, 24-34.
7. Chang, P.L., Cao, M. & Hicks, P. (2003) Osteopontin induction is required for tumor promoter-induced transformation of pre-neoplastic mouse cells. Carcinogenesis, 24, 1749-1758.
8. Cichy, J. & Pure, E. (2003) The liberation of CD44. Journal of Cellular Biology, 161, 839-843.
9. Finco, T.S., Westwick, J.K., Norris, J.L., Beg, A.A., Der, C.J. & Baldwin, A.S., (1997) Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. Journal of Biological Chemistry, 272, 24113-24116.
10. Flamant, S., Kortulewsky, T., Dugray, M.L., Bonnet, M.L., Guillier, F., Guilhot, F., Bourhis, J.H. & Vainchenker, W.D. (2003) Osteopotnin is a target of Bcr-Abl oncogene. Blood, 102(Suppl. 1), abstract 477.
11. Frisch, S.M., Vuori, K., Kelaita, D. & Sicks, S. (1996) A role for Jun-N-terminal kinase in anoikis; suppression by bcl-2 and crmA. Journal of Cellular Biology, 135, 1377-1382.
12. Frost, J.A., Swantek, J.L., Stippec, S., Yin, M.J., Gaynor, R. & Cobb, M.H. (2000) Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1. Journal of Biological Chemistry, 275, 19693-19699.
13. Furger, K.A., Menon, R.K., Tuckl, A.B., Bramwelll, V.H. & Chambers, A.F. (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Current Molecular Medicine, 1, 621-632.
14. Gaiger, A., Henn, T., Horth, E., Geissler, K., Mitterbauer, G., Maier-Dobersberger, T., Greinix, H., Mannhalter, C., Haas, O.A., Lechner, K. & Lion, T. (1995) Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood, 86, 2371-2378.
15. Gardner, H.A., Berse, B. & Senger, D.R. (1994) Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene, 9, 2321-2326.
16. Ghaffari, S., Smadja-Joffe, F., Oostendorp, R., Levesque, J.P., Dougherty, G., Eaves, A. & Eaves, C. (1999) CD44 isoforms in normal and leukemic hematopoiesis. Experimental Hematology, 27, 978-993.
17. Ghosh, S. & Karin, M. (2002) Missing pieces in the NF-kappaB puzzle. Cell, 109(suppl.), S81-S96.
18. Ghosh, S., May, M.J. & Kopp, E.B. (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annual Review of Immunology, 16, 225-260.
19. Guinn, B.A., Evely, R.S., Walsh, V., Gilkes, A.F., Burnett, A.K. & Mills, K.I. (2000) An in vivo and in vitro comparison of the effects of b2-a2 and b3-a2 p210BCR-ABL splice variants on murine 32D cells. Leukemia and Lymphorna, 37, 393-404.
20. Hamdane, M., David-Cordonnier, M.H. & D'Halluin, J.C. (1997) Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene, 15, 2267-2275.
21. Hanahan, D. & Weinberg, R.A. (2000) The hallmarks of cancer. Cell, 100, 57-70.
22. Kantarjian, H.M., Keating, M.J., Talpaz, M., Walters, R.S., Smith, T.L., Cork, A., McCredie, K.B. & Freireich, E.J. (1987) Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. The American Journal of Medicine, 83, 445-454.
23. Kasugai, S., Zhang, Q., Overall, C.M., Wrana, J.L., Butler, W.T. & Sodek, J. (1991) Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter. Bone Mineralisation, 13, 235-250.
24. Katagiri, Y.U., Sleeman, J., Fujii, H., Herrlich, P., Hotta, H., Tanaka, K., Chikuma, S., Yagita, H., Okumura, K., Murakami, M., Saiki, I., Chambers, A.F. & Uede, T. (1999) CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Research, 59, 219-226.
25. Keeshan, K., Mills, K.I., Cotter, T.G. & McKenna, S.L. (2001) Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia, 15, 1823-1833.
26. Keeshan, K., Cotter, T.G. & McKenna, S.L. (2002) High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion. Leukemia, 16, 1725-1734.
27. Keeshan, K., Cotter, T.G. & McKenna, S.L. (2003) Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway. British Journal of Haematology, 123, 34-44.
28. Khan, S.A., Lopez-Chua, C.A., Zhang, J., Fisher, L.W., Sorensen, E.S. & Denhardt, D.T. (2002) Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. Journal of Cellular Biochemistry, 85, 728-736.
29. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P.H. & Downward, J. (1997) Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. The EMBO Journal, 16, 2783-2793.
30. Kirchner, D., Duyster, J., Ottmann, O., Schmid, R.M., Bergmann, L. & Munzert, G. (2003) Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. Experimental Hematology, 31, 504-511.
31. Liaw, L., Lindner, V., Schwartz, S.M., Chambers, A.F. & Giachelli, C.M. (1995) Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circulation Research, 77, 665-672.
32. Lopez, C.A., Davis, R.L., Mou, K. & Denhardt, D.T. (1995) Activation of a signal transduction pathway by osteopontin. Annals of the New York Academy of Sciences, 760, 324-326.
33. Mayo, M.W., Wang, C.Y., Cogswell, P.C., Rogers-Graham, K.S., Lowe, S.W., Der, C.J. & Baldwin, A.S., (1997) Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science, 278, 1812-1815.
34. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K.M., Green, D.R. & Cotter, T.G. (1994) Bcr-Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood, 83, 1179-1187.
35. Oates, A.J., Barraclough, R. & Rudland, P.S. (1996) The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene, 13, 97-104.
36. Philip, S., Bulbule, A. & Kundu, G.C. (2001) Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. Journal of Biological Chemistry, 276, 44926-44935.
37. Reuther, J.Y., Reuther, G.W., Cortez, D., Pendergast, A.M. & Baldwin, A.S., (1998) A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes and Development, 12, 968-981.
38. Scatena, M., Almeida, M., Chaisson, M.L., Fausto, N., Nicosia, R.F. & Giachelli, C.M. (1998) NF-kappaB mediates alphavbeta3 integrininduced endothelial cell survival. Journal of Cellular Biology, 141, 1083-1093.
39. Senftleben, U., Li, Z.W., Baud, V. & Karin, M. (2001) IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis. Immunity, 14, 217-230.
40. Senger, D.R., Wirth, D.F. & Hynes, R.O. (1979) Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell, 16, 885-893.
41. Shanmugam, V., Chackalaparampil, I., Kundu, G.C., Mukherjee, A.B. & Mukherjee, B.B. (1997) Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells. Biochemistry, 36, 5729-5738.
42. Singh, K., DeVouge, M.W. & Mukherjee, B.B. (1990) Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated forms of osteopontin secreted by normal rat kidney cells. Journal of Biological Chemistry, 265, 18696-18701.
43. Singhal, H., Bautista, D.S., Tonkin, K.S., O'Malley, P.P., Tuck, A.B., Chambers, A.F. & Harris, J.F. (1997) Elevated plasma Osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clinical Cancer Research, 3, 605-611.
44. Sodek, J., Ganss, B. & McKee, M.D. (2000) Osteopontin. Critical Reviews in Oral Biology and Medicine, 11, 279-303.
45. Steelman, L.S., Pohnert, S.C., Shelton, J.G., Franklin, R.A., Bertrand, F.E. & McCubrey, J.A. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and Bcr-Abl in cell cycle progression and leukemogenesis. Leukemia, 18, 189-218.
46. Su, L., Mukherjee, A.B. & Mukherjee, B.B. (1995) Expression of anti-sense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. Oncogene, 10, 2163-2169.
47. Teti, A., Farina, A.R., Villanova, I., Tiberio, A., Tacconelli, A., Sciortino, G., Chambers, A.F., Gulino, A. & Mackay, A.R. (1998) Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. International Journal of Cancer, 77, 82-93.
48. Tuck, A.B., O'Malley, F.P., Singhal, H., Tonkin, K.S., Harris, J.F., Bautista, D. & Chambers, A.F. (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Archives of Pathology and Laboratory Medicine, 121, 578-584.
49. Tuck, A.B., Arsenault, D.M., O'Malley, F.P., Hota, C., Ling, M.C., Wilson, S.M. & Chambers, A.F. (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene, 18, 4237-4246.
50. Tuck, A.B., Elliott, B.E., Hota, C., Tremblay, E. & Chambers, A.F. (2000) Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). Journal of Cellular Biochemistry, 78, 465-475.
51. Weber, G.F., Adler, B. & Ashkar, S. (1999) Osteopontin in oxidative stress response. In: Inflammatory Cells and Mediators in CNS Diseases (ed. by J.R. Ruffolo, G.Z. Feuerstein, A.J. Hunter, G. Poste & B.W. Metcalf), pp. 97-112. Harwood Academic Amsterdam, Amsterdam.
52. Zimolo, Z., Wesolowski, G., Tanaka, H., Hyman, J.L., Hoyer, J.R. & Rodan, G.A. (1994) Soluble alpha v beta 3-integrin ligands raise [Ca2+]i in rat osteoclasts and mouse-derived osteoclast-like cells. American Journal of Physiology, 266, C376-381.